Paget's disease is a common
skeletal disorder that can lead to bone deformity, fractures,
osteoarthritis, and bone pain. In a study of patients with Paget's disease of bone, long-term intensive bisphosphonate
therapy conferred no clinical benefit over giving bisphosphonates only
when patients felt bone pain.
Also, long-term bisphosphonate therapy was linked with a
non-significant increase in the risk of fractures and serious adverse
‘Long-term intensive bisphosphonate therapy, for patients with Paget's disease of bone, conferred no clinical benefit over giving bisphosphonates only when patients felt bone pain.’
Although bisphosphonates are effective at suppressing the elevated
bone turnover and bone pain that are characteristic of Paget's disease
of bone, the study's results suggest that the drugs should be used to
control symptoms rather than to suppress bone turnover.
"This is an important study since it shows that clinicians involved
in the management of Paget's disease should be treating the patient and
not biochemical markers of bone turnover," said Dr. Stuart Ralston,
senior author of the Journal of Bone and Mineral Research
study. "Bisphosphonates are effective drugs for the treatment of Paget's
but our study suggests that striving to normalize biochemical markers
may be harmful."